From Structure to Clinical Development: Allosteric Modulation of G Protein-Coupled Receptors

From Structure to Clinical Development: Allosteric Modulation of G Protein-Coupled Receptors, Volume 88, the latest release in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this updated edition include Targeting muscarinic M1 receptor in neurodegeneration, Photo-switchable allosteric ligands, Computational approaches for the design of mGlu receptor allosteric modulators, Allosteric modulation of GLP-1 receptor in metabolic disorders, Group II mGluR roles in the nervous system and their roles in addiction, RAMPs as allosteric modulators of Class B GPCRs, Structure-based discovery and development of mGlu5 NAMs, and much more.

1. The computational modeling of allosteric modulation of metabotropic glutamate receptors

Laura Pérez-Benito, Claudia Llinas del Torrent, Leonardo Pardo and Gary Tresadern

2. Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators

Kirstie A. Bennett, John A. Christopher and Benjamin G. Tehan

3. The function and allosteric control of the human sweet taste receptor

Guy Servant, Terry Kenakin, Lan Zhang, Mark Williams and Nicole Servant

4. The different aspects of the GABA_B receptor allosteric modulation

Julie Kniazeff

5. RAMPs as allosteric modulators of the calcitonin and calcitonin-like class B G protein-coupled receptors

Augen A. Pioszak and Debbie L. Hay

6. Strategies and considerations of G-protein-coupled receptor photopharmacology

Alice E. Berizzi and Cyril Goudet

7. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP. A novel tool to probe GLP-1R pharmacology

Francis S. Willard, Joseph D. Ho and Kyle W. Sloop

8. Allosteric modulation of metabotropic glutamate receptors in alcohol use disorder: Insights from preclinical investigations

Kari A. Johnson and David M. Lovinger

9. Allosteric modulation of muscarinic receptors in alcohol and substance use disorders

Leigh C. Walker and Andrew J. Lawrence

10. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?